




RealRate

PHARMACEUTICAL 2021

NeuroBo Pharmaceuticals Inc.
Rank 402 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

NeuroBo Pharmaceuticals Inc. Rank 402 of 409

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 111% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 919% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,528%, being 1,173% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	10,683
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,695
Liabilities, Non-Current	70
Other Assets	130
Other Compr. Net Income	2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	38
Property and Equipment	155
Research and Development	21,870
Revenues	0
Selling, General and Administrative Expense	7,846

Output Variable	Value in 1000 USD
Assets	10,968
Liabilities	3,765
Expenses	29,716
Stockholders Equity	7,203
Net Income	-29,678
Comprehensive Net Income	-29,677
Economic Capital Ratio	-1,528%

